DISITAMAB VEDOTIN COMBINED WITH PYROTINIB AS SALVAGE TREATMENT IN HER-2-AMPLIFIED TREATMENT REFRACTORY METASTATIC COLORECTAL CANCER: A CASE REPORT

Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report

BackgroundHuman epidermal growth factor receptor 2 (HER-2) amplification has been identified in approximately 3% of patients with metastatic colorectal cancer (mCRC).Owing to the lack of established anti-ERBB2 therapeutic approaches, rab fire rated wafer mCRC patients with Her-2 amplification rarely receive targeted treatments.Moreover, conventiona

read more

Similarly Lethal Strains of Extraintestinal Pathogenic Escherichia coli Trigger Markedly Diverse Host Responses in a Zebrafish Model of Sepsis

ABSTRACT In individuals with sepsis, the infecting microbes are commonly viewed as generic inducers of inflammation while the host background is considered the primary variable affecting disease progression and outcome.To study the effects of bacterial strain differences on the maladaptive immune responses that are induced during sepsis, we employe

read more

Role of liquid biopsy for thoracic cancers immunotherapy

Immunotherapy has shifted the therapeutic landscape in thoracic cancers.However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the lack of tissue sample availability for clinical and research purposes.In this scenario, liquid biopsy (LB), defined as the study and characterization of

read more

BOA: A partitioned view of genome assembly

Summary: De novo genome assembly is a fundamental problem in computational molecular biology that aims to reconstruct an unknown genome sequence from 2003 lexus es300 coolant type a set of short DNA sequences (or reads) obtained from the genome.The relative ordering of the reads along the target genome is not known a priori, which is one of the mai

read more